Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.
Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.
Advanced imaging techniques may be able to distinguish which patients’ tumors will respond to treatment with antiangiogenic drugs and which will not.
